Market Cap | 190.40B | P/E | 30.23 | EPS this Y | 0.50% | Ern Qtrly Grth | -51.70% |
Income | 4.2B | Forward P/E | 29.24 | EPS next Y | 13.60% | 50D Avg Chg | 7.00% |
Sales | 23.89B | PEG | 12.84 | EPS past 5Y | 19.15% | 200D Avg Chg | 3.00% |
Dividend | N/A | Price/Book | 3.68 | EPS next 5Y | 2.54% | 52W High Chg | -15.00% |
Recommedations | 2.00 | Quick Ratio | 1.28 | Shares Outstanding | 739.70M | 52W Low Chg | 17.00% |
Insider Own | 10.75% | ROA | 3.98% | Shares Float | 688.43M | Beta | 0.86 |
Inst Own | 81.83% | ROE | 8.15% | Shares Shorted/Prior | 5.66M/5.80M | Price | 257.87 |
Gross Margin | 59.14% | Profit Margin | 19.94% | Avg. Volume | 3,288,670 | Target Price | 260.70 |
Oper. Margin | 20.87% | Earnings Date | Apr 23 | Volume | 2,545,214 | Change | 1.13% |
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.
Keybanc | Overweight | Feb 1, 24 |
Citigroup | Buy | Jan 31, 24 |
RBC Capital | Outperform | Jan 31, 24 |
Raymond James | Outperform | Jan 31, 24 |
Barclays | Equal-Weight | Jan 24, 24 |
JP Morgan | Overweight | Dec 20, 23 |
HSBC | Hold | Dec 18, 23 |
Wolfe Research | Peer Perform | Dec 13, 23 |
Citigroup | Buy | Dec 11, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Gutierrez-Ramos Jose-Carlos | SVP, Chief Science O.. SVP, Chief Science Officer | Aug 21 | Sell | 250.54 | 590 | 147,819 | 6,939 | 08/22/23 |
Weidemanis Joakim | Executive Vice Presi.. Executive Vice President | Jul 26 | Sell | 263.42 | 22,439 | 5,910,881 | 88,689 | 07/27/23 |
Weidemanis Joakim | Executive Vice Presi.. Executive Vice President | Jul 26 | Option | 56.7 | 22,439 | 1,272,291 | 111,128 | 07/27/23 |
List Teri | Director Director | Jul 26 | Sell | 263.3 | 3,490 | 918,917 | 17,494 | 07/27/23 |
List Teri | Director Director | Jul 26 | Option | 50.8 | 3,490 | 177,292 | 20,984 | 07/27/23 |
Raskas Daniel | SVP - Corporate Deve.. SVP - Corporate Development | May 31 | Sell | 228.5 | 19,847 | 4,535,040 | 38,673 | 06/01/23 |
Raskas Daniel | SVP - Corporate Deve.. SVP - Corporate Development | May 31 | Option | 57.9 | 19,847 | 1,149,141 | 58,520 | 06/01/23 |
LOHR WALTER G | Director Director | May 05 | Sell | 240.88 | 3,490 | 840,671 | 12,115 | 05/08/23 |
LOHR WALTER G | Director Director | May 05 | Option | 50.8 | 3,490 | 177,292 | 15,605 | 05/08/23 |
Couchara Georgeann | SVP, Human Resources SVP, Human Resources | Nov 15 | Sell | 271.61 | 1,884 | 511,713 | 2,588 | 11/16/22 |
McGrew Matthew | EVP & Chief Financia.. EVP & Chief Financial Officer | Nov 11 | Option | 57.3 | 18,935 | 1,084,976 | 40,847 | 11/14/22 |
McGrew Matthew | EVP & Chief Financia.. EVP & Chief Financial Officer | Nov 11 | Sell | 274.67 | 18,935 | 5,200,876 | 29,634 | 11/14/22 |
Honeycutt Jennifer | Executive Vice Presi.. Executive Vice President | Nov 10 | Option | 65.83 | 8,211 | 540,530 | 15,373 | 11/14/22 |
Honeycutt Jennifer | Executive Vice Presi.. Executive Vice President | Nov 10 | Sell | 265 | 8,211 | 2,175,915 | 7,162 | 11/14/22 |
Blair Rainer | President & CEO President & CEO | Aug 15 | Option | 68.29 | 25,000 | 1,707,250 | 104,739 | 08/17/22 |
Blair Rainer | President & CEO President & CEO | Aug 15 | Sell | 300 | 25,000 | 7,500,000 | 79,739 | 08/17/22 |
Weidemanis Joakim | Executive Vice Presi.. Executive Vice President | Jul 25 | Sell | 271.56 | 12,000 | 3,258,720 | 74,398 | 07/26/22 |
LOHR WALTER G | Director Director | Jul 22 | Option | 38.64 | 4,548 | 175,735 | 16,663 | 07/25/22 |
LOHR WALTER G | Director Director | Jul 22 | Sell | 273.84 | 3,906 | 1,069,619 | 12,115 | 07/25/22 |
SCHWIETERS JOHN T | Director Director | Jul 13 | Option | 38.64 | 4,548 | 175,735 | 18,663 | 07/14/22 |
Weidemanis Joakim | Executive Vice Presi.. Executive Vice President | Apr 25 | Sell | 255.735 | 6,500 | 1,662,278 | 86,398 | 04/27/22 |
Ellis Brian W | Senior Vice Presiden.. Senior Vice President - GC | Feb 02 | Sell | 293.9884 | 5,365 | 1,577,248 | 12,374 | 02/03/22 |
Weidemanis Joakim | Executive Vice Presi.. Executive Vice President | Jan 31 | Option | 46.13 | 20,508 | 946,034 | 84,351 | 02/02/22 |
Weidemanis Joakim | Executive Vice Presi.. Executive Vice President | Jan 31 | Sell | 285.24 | 20,508 | 5,849,702 | 63,843 | 02/02/22 |
RALES MITCHELL P | Chairman of Exec. Co.. Chairman of Exec. Committee | Nov 02 | Sell | 308.71 | 1,225,841 | 378,429,375 | 11/04/21 | |
LUTZ ROBERT S | SVP-Chief Accounting.. SVP-Chief Accounting Officer | Oct 27 | Option | 46.13 | 24,594 | 1,134,521 | 43,544 | 10/27/20 |
LUTZ ROBERT S | SVP-Chief Accounting.. SVP-Chief Accounting Officer | Oct 27 | Sell | 234.37 | 24,594 | 5,764,096 | 18,950 | 10/27/20 |
COMAS DANIEL L | EVP EVP | Oct 27 | Option | 65.83 | 54,402 | 3,581,284 | 109,607 | 10/27/20 |
COMAS DANIEL L | EVP EVP | Oct 27 | Sell | 233.99 | 54,402 | 12,729,524 | 92,683 | 10/27/20 |